You are here: Products\Immunoassays\Fetuin-A (AHSG) Human ELISA:

Fetuin-A (AHSG) Human ELISA

Other names: Alpha-2-HS-glycoprotein, Ba-alpha-2-glycoprotein, Alpha-2-Z-globulin, Fetuin A, AHSG, FETUA, PRO2743 Product of BioVendor
Product: Size:
RD191037100 (regulatory status: RUO) 96 wells (1 kit)
RD191037100 (regulatory status: IVD CE) 96 wells (1 kit)
Files: Datasheet PDF (RUO)Datasheet PDF (IVD CE)MSDS (RUO)MSDS (IVD CE)Product Description Fetuin-A on pubmed

Product details


Summary

Fetuin-A (AHSG), a 59 kDa glycoprotein, consists of two cystatin-like domains and a smaller unrelated domain. Its homologues have been identified in several species including rat (pp63), mouse, guinea pig, rabbit, sheep, cattle, swine and human. AHSG human gene is located on chromosome 3q27. Liver synthesized fetuin-A is secreted into the blood stream and it is deposited as a noncollagenous protein in mineralized bones and teeth. Fetuin-A occurs in high serum concentration during fetal life, whereas its level declines following infection, inflammation (by 20–30% during acute phase) and malignancy. Fetuin-A may influence the resolution of inflammation by modulating the phagocytosis of apoptotic cells by macrophages. Fetuin-A acts as an important circulating inhibitor of ectopic calcification that is a frequent complication of many degenerative diseases. The low fetuin-A level may be associated with higher cardiovascular mortality in chronic renal failure, liver cancer and liver cirrhosis patients on long-term dialysis. Human fetuin-A represents a natural inhibitor of tyrosine kinase activity of the insulin receptor. Fetuin-A may play a significant role in regulating postprandial glucose disposal, insulin sensitivity, weight gain, and fat accumulation and may be a novel therapeutic target in the treatment of type 2 diabetes, obesity, and other insulin-resistant conditions. The serum and bone-resident fetuin-A binds to transforming growth factor-β and blocks TGF-β binding to cell surface receptors. Thus, fetuin-A is involved at least in inhibition of unwanted (vascular) calcification, inhibition of insulin receptor tyrosine kinase activity and regulation of osteogenesis.

Features

  • European Union: for in vitro diagnostic use
  • Rest of the world: for research use only!
  • The total assay time is less than 3 hours
  • The kit measures fetuin-A in serum and plasma (EDTA, citrate, heparin)
  • Assay format is 96 wells
  • Quality Controls are human serum based. No animal sera are used
  • Standard is human plasma based
  • Components of the kit are provided ready to use, concentrated or lyophilized

Research topic

Bone and cartilage metabolism, Cardiovascular disease, Renal disease


Assay format

Sandwich ELISA, HRP-labelled antibody

Applications

Plasma-Citrate, Plasma-EDTA, Plasma-Heparin, Serum

Sample requirements

10 µl/well

Storage/Shipping

Store the kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration range

2–100 ng/ml

Limit of detection

0.104 ng/ml

Intra-assay (Within-Run, n=8)

CV = 2.9%

Inter-assay (Run-to-Run, n=6)

CV = 4.7%

Spiking Recovery

108.8%

Dilution Linearity

110.4%

Cross-Reactivity

human Yes
bovine Non-detectable
cat Non-detectable
chicken Not tested
dog Non-detectable
goat Non-detectable
hamster Non-detectable
horse Non-detectable
monkey Yes (recommended dilution 1:5000)
mouse Non-detectable
pig Non-detectable
rabbit Non-detectable
rat Non-detectable
sheep Non-detectable

References to this product

  • Abali R, Celik C, Tasdemir N, Guzel S, Alpsoy S, Yuksel A, Celik E. The serum protein alpha2-Heremans-Schmid glycoprotein/fetuin-a concentration and carotid intima-media thickness in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Bi. 2013 Jul;169 (1):45-9
  • Argani H, Ghorbanihaghjo A, Panahi G, Rashtchizadeh N, Safa J, Meimand SM. Serum Fetuin-A and Pentraxin3 in hemodialysis and renal transplant patients. Clin Biochem. 2012 Jul;45 (10-11):775-9
  • Blaha V, Mistrik E, Dusilova-Sulkova S, Kalousova M, Andrys C, Blaha M, Sobotka L. Circulating fetuin-A predicts early mortality in chronic hemodialysis patients. Clin Biochem. 2009 Jul;42 (10-11):996-1000
  • Brettschneider J, Lehmensiek V, Mogel H, Pfeifle M, Dorst J, Hendrich C, Ludolph AC, Tumani H. Proteome analysis reveals candidate markers of disease progression in amyotrophic lateral sclerosis (ALS). Neurosci Lett. 2010 Jan 1;468 (1):23-7
  • Briana DD, Boutsikou M, Gourgiotis D, Boutsikou T, Baka S, Marmarinos A, Hassiakos D, Malamitsi-Puchner A. Serum fetuin-A/alpha2-HS-glycoprotein in human pregnancies with normal and restricted fetal growth. J Matern Fetal Neonatal Med. 2008 Nov;21 (11):826-30
  • Brix JM, Stingl H, Hollerl F, Schernthaner GH, Kopp HP, Schernthaner G. Elevated Fetuin-A concentrations in morbid obesity decrease after dramatic weight loss. J Clin Endocrinol Metab. 2010 Nov;95 (11):4877-81
  • Caglar K, Yilmaz MI, Saglam M, Cakir E, Acikel C, Eyileten T, Yenicesu M, Oguz Y, Vural A, Carrero JJ, Axelsson J, Lindholm B, Stenvinkel P. Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. Clin J Am Soc Nephrol. 2008 Jan;3 (1):61-8
  • Caglar K, Yilmaz MI, Saglam M, Cakir E, Kilic S, Sonmez A, Eyileten T, Yenicesu M, Oguz Y, Tasar M, Vural A, Ikizler TA, Stenvinkel P, Lindholm B. Serum fetuin-a concentration and endothelial dysfunction in chronic kidney disease. Nephron Clin Pract. 2008;108 (3):c233-40
  • Cagli K, Basar N, Cagli K, Armutcu F, Aylak F, Yalcinkaya A, Erden G, Kadirogullari E. Association of serum fetuin-A with valvular calcium concentration in rheumatic mitral valve disease. J Heart Valve Dis. 2010 Sep;19 (5):636-43
  • Cianciolo G, La Manna G, Donati G, Persici E, Dormi A, Cappuccilli ML, Corsini S, Fattori R, Russo V, Nastasi V, Coli L, Wratten M, Stefoni S. Coronary calcifications in end-stage renal disease patients: a new link between osteoprotegerin, diabetes and body mass index?. Blood Purif. 2010;29 (1):13-22
  • Cutler P, Akuffo EL, Bodnar WM, Briggs DM, Davis JB, Debouck CM, Fox SM, Gibson RA, Gormley DA, Holbrook JD, Hunter AJ, Kinsey EE, Prinjha R, Richardson JC, Roses AD, Smith MA, Tsokanas N, Willé DR, Wu W, Yates JW, Gloger IS. Proteomic identification and early validation of complement 1 inhibitor and pigment epithelium-derived factor: Two novel biomarkers of Alzheimer's disease in human plasma. Proteomics. 7 Mar 2008;2 Issue 4:467 - 477
  • Dalamaga M, Karmaniolas K, Chamberland J, Nikolaidou A, Lekka A, Dionyssiou-Asteriou A, Mantzoros CS. Higher fetuin-A, lower adiponectin and free leptin levels mediate effects of excess body weight on insulin resistance and risk for myelodysplastic syndrome. Metabolism. 2013 Dec;62 (12):1830-9
  • Dervisoglu E, Kir HM, Kalender B, Caglayan C, Eraldemir C. Serum fetuin--a concentrations are inversely related to cytokine concentrations in patients with chronic renal failure. Cytokine. 2008 Dec;44 (3):323-7
  • Eller P, Hochegger K, Feuchtner GM, Zitt E, Tancevski I, Ritsch A, Kronenberg F, Rosenkranz AR, Patsch JR, Mayer G. Impact of ENPP1 genotype on arterial calcification in patients with end-stage renal failure. Nephrol Dial Transplant. 2008 Jan;23 (1):321-7
  • Emoto M, Mori K, Lee E, Kawano N, Yamazaki Y, Tsuchikura S, Morioka T, Koyama H, Shoji T, Inaba M, Nishizawa Y. Fetuin-A and atherosclerotic calcified plaque in patients with type 2 diabetes mellitus. Metabolism. 2010 Jun;59 (6):873-8
  • Eraso LH, Ginwala N, Qasim AN, Mehta NN, Dlugash R, Kapoor S, Schwartz S, Schutta M, Iqbal N, Mohler ER 3rd, Reilly MP. Association of lower plasma fetuin-a levels with peripheral arterial disease in type 2 diabetes. Diabetes Care. 2010 Feb;33 (2):408-10
  • Ford ML, Tomlinson LA, Smith ER, Rajkumar C, Holt SG. Fetuin-A is an independent determinant of change of aortic stiffness over 1 year in non-diabetic patients with CKD stages 3 and 4. Nephrol Dial Transplant. 2010 Jan 14;
  • Hamano T, Matsui I, Mikami S, Tomida K, Fujii N, Imai E, Rakugi H, Isaka Y. Fetuin-mineral complex reflects extraosseous calcification stress in CKD. J Am Soc Nephrol. 2010 Nov;21 (11):1998-2007
  • Harris VK, Donelan N, Yan QJ, Clark K, Touray A, Rammal M, Sadiq SA. Cerebrospinal fluid fetuin-A is a biomarker of active multiple sclerosis. Mult Scler. 2013 Oct;19 (11):1462-72
  • Hennige AM, Staiger H, Wicke C, Machicao F, Fritsche A, Haring HU, Stefan N. Fetuin-A induces cytokine expression and suppresses adiponectin production. PLoS One. 2008;3 (3):e1765
  • Hussein NA, Mahmoud OM, Zahran MY, Rafaat MA. Serum Fetuin-A in Chronic Renal Disease Patients: Contribution to Endothelial Dysfunction and Hemostatic alteration. Journal of American Science. 2010;6(12);
  • Hwang JJ, Thakkar B, Chamberland JP, Mantzoros CS. Circulating fetuin-A levels are not affected by short and long-term energy deprivation and/or by leptin administration. Metabolism. 2014 Feb 17;
  • Ishibashi A, Ikeda Y, Ohguro T, Kumon Y, Yamanaka S, Takata H, Inoue M, Suehiro T, Terada Y. Serum fetuin-A is an independent marker of insulin resistance in Japanese men. J Atheroscler Thromb. 2010 Sep 30;17 (9):925-33
  • Jimenez MC, Sun Q, Schurks M, Hu FB, Manson JE, Rexrode KM. Circulating fetuin-a and risk of ischemic stroke in women. Clin Chem. 2014 Jan;60 (1):165-73
  • Kaden JJ, Reinohl JO, Blesch B, Brueckmann M, Haghi D, Borggrefe M, Schmitz F, Klomfass S, Pillich M, Ortlepp JR. Systemic and local levels of fetuin-A in calcific aortic valve stenosis. Int J Mol Med. 2007 Aug;20 (2):193-7
  • Kaess BM, Enserro DM, McManus DD, Xanthakis V, Chen MH, Sullivan LM, Ingram C, O'Donnell CJ, Keaney JF, Vasan RS, Glazer NL. Cardiometabolic correlates and heritability of fetuin-a, retinol-binding protein 4, and Fatty-Acid binding protein 4 in the framingham heart study. J Clin Endocrinol Metab. 2012 Oct;97 (10):E1943-7
  • Kamel AA, El-Attar HA, Abaza MM, Gaber EW, Badawi SS. Study of serum osteoprotegerin (OPG), tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and fetuin-A in patients with chronic renal failure. Bull. Alex. Fac. Med. 2007;43 (3)
  • Kanbay M, Nicoleta M, Selcoki Y, Ikizek M, Aydin M, Eryonucu B, Duranay M, Akcay A, Armutcu F, Covic A. Fibroblast growth factor 23 and fetuin A are independent predictors for the coronary artery disease extent in mild chronic kidney disease. Clin J Am Soc Nephrol. 2010 Oct;5 (10):1780-6
  • Katayama H, Paczesny S, Prentice R, Aragaki A, Faca VM, Pitteri SJ, Zhang Q, Wang H, Silva M, Kennedy J, Rossouw J, Jackson R, Hsia J, Chlebowski R, Manson J, Hanash S. Application of serum proteomics to the Women's Health Initiative conjugated equine estrogens trial reveals a multitude of effects relevant to clinical findings. Genome Med. 2009;1 (4):47
  • Kaushik SV, Plaisance EP, Kim T, Huang EY, Mahurin AJ, Grandjean PW, Mathews ST. Extended-release niacin decreases serum fetuin-A concentrations in individuals with metabolic syndrome. Diabetes Metab Res Rev. 2009 Jul;25 (5):427-34
  • Kloting N, Fasshauer M, Dietrich A, Kovacs P, Schon MR, Kern M, Stumvoll M, Bluher M. Insulin-sensitive obesity. Am J Physiol Endocrinol Metab. 2010 Sep;299 (3):E506-15
  • Kusnierz-Cabala B, Gurda-Duda A, Panek J, Fedak D, Dumnicka P, Solnica B, Kulig J. Serum fetuin A concentrations in patients with acute pancreatitis. Clin Lab. 2010;56 (5-6):191-5
  • Liu X, Hamnvik OP, Chamberland JP, Petrou M, Gong H, Christophi CA, Christiani DC, Kales SN, Mantzoros CS. Circulating alanine transaminase (ALT) and gamma-glutamyl transferase (GGT), but not fetuin-A, are associated with metabolic risk factors, at baseline and at two-year follow-up: The prospective Cyprus Metabolism Study. Metabolism. 2014 Mar 15;
  • Lorant DP, Grujicic M, Hoebaus C, Brix JM, Hoellerl F, Schernthaner G, Koppensteiner R, Schernthaner GH. Fetuin-A levels are increased in patients with type 2 diabetes and peripheral arterial disease. Diabetes Care. 2011 Jan;34 (1):156-61
  • Lorenzen JM, Martino F, Scheffner I, Brocker V, Leitolf H, Haller H, Gwinner W. Fetuin, matrix-gla protein and osteopontin in calcification of renal allografts. PLoS One. 2012;7 (12):e52039
  • Maharem DA, Gomaa SH, El Ghandor MK, Mohamed EI, Matrawy KA, Zaytoun SS, Nomeir HM. Association of serum fetuin-A and fetuin-A gene polymorphism in relation to mineral and bone disorders in patients with chronic kidney disease. Eg. J. Hum. Genet.. September 2013;
  • Mori K, Emoto M, Araki T, Yokoyama H, Teramura M, Lee E, Motoyama K, Koyama H, Shoji T, Inaba M, Nishizawa Y. Association of serum fetuin-A with carotid arterial stiffness. Clin Endocrinol (Oxf) . Feb;66(2):246-50 (2007)
  • Mori K, Emoto M, Yokoyama H, Araki T, Teramura M, Koyama H, Shoji T, Inaba M, Nishizawa Y. Association of serum fetuin-A with insulin resistance in type 2 diabetic and nondiabetic subjects. Diabetes Care . Feb;29(2):468 (2006)
  • Oikawa O, Higuchi T, Yamazaki T, Yamamoto C, Fukuda N, Matsumoto K. Evaluation of serum fetuin-A relationships with biochemical parameters in patients on hemodialysis. Clin Exp Nephrol. 2007 Dec;11 (4):304-8
  • Ou HY, Yang YC, Wu HT, Wu JS, Lu FH, Chang CJ. Increased fetuin-A concentrations in impaired glucose tolerance with or without nonalcoholic fatty liver disease, but not impaired fasting glucose. J Clin Endocrinol Metab. 2012 Dec;97 (12):4717-23
  • Panczyk-Tomaszewska M, Skrzypczyk P, Ziolkowska H, Adamczuk D, Roszkowska-Blaim M. [Fetuin A in children with nephrotic syndrome]. Pol Merkur Lekarski. 2008;24 Suppl 4:65-7
  • Pertosa G, Simone S, Ciccone M, Porreca S, Zaza G, Dalfino G, Memoli B, Procino A, Bonomini M, Sirolli V, Castellano G, Gesualdo L, Ktena M, Schena FP, Grandaliano G. Serum fetuin a in hemodialysis: a link between derangement of calcium-phosphorus homeostasis and progression of atherosclerosis?. Am J Kidney Dis. 2009 Mar;53 (3):467-74
  • Petrik V, Saadoun S, Loosemore A, Hobbs J, Opstad KS, Sheldon J, Tarelli E, Howe FA, Bell BA, Papadopoulos MC. Serum alpha 2-HS glycoprotein predicts survival in patients with glioblastoma. Clin Chem. 2008 Apr;54 (4):713-22
  • Roos M, Richart T, Kouznetsova T, von Eynatten M, Lutz J, Heemann U, Baumann M, Staessen JA. Fetuin-A and arterial stiffness in patients with normal kidney function. Regul Pept. 2009 Apr 10;154 (1-3):39-43
  • Sigrist MK, Levin A, Er L, McIntyre CW. Elevated osteoprotegerin is associated with all-cause mortality in CKD stage 4 and 5 patients in addition to vascular calcification. Nephrol Dial Transplant. 2009 Oct;24 (10):3157-62
  • Sigrist MK, Taal MW, Bungay P, McIntyre CW. Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. Clin J Am Soc Nephrol. 2007 Nov;2 (6):1241-8
  • Smith ER, Cai MM, McMahon LP, Pedagogos E, Toussaint ND, Brumby C, Holt SG. Serum fetuin-A concentration and fetuin-A-containing calciprotein particles in patients with chronic inflammatory disease and renal failure. Nephrology (Carlton). 2013 Mar;18 (3):215-21
  • Smith ER, Ford ML, Tomlinson LA, Rocks BF, Rajkumar C, Holt SG. Poor agreement between commercial ELISAs for plasma fetuin-A: An effect of protein glycosylation?. Clin Chim Acta. 2010 Sep 6;411 (17-18):1367-70
  • Stefan N, Hennige AM, Staiger H, Machann J, Schick F, Krober SM, Machicao F, Fritsche A, Haring HU. Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care . Apr;29(4):853-7 (2006)
  • Stejskal D, Karpisek M, Vrtal R, Student V, Solichova P, Fiala R, Stejskal P. Urine fetuin-A values in relation to the presence of urolithiasis. BJU Int. 2008 May;101 (9):1151-4
  • Tonjes A, Fasshauer M, Kratzsch J, Stumvoll M, Bluher M. Adipokine pattern in subjects with impaired fasting glucose and impaired glucose tolerance in comparison to normal glucose tolerance and diabetes. PLoS One. 2010;5 (11):e13911
  • Tumani H, Lehmensiek V, Rau D, Guttmann I, Tauscher G, Mogel H, Palm C, Hirt V, Suessmuth SD, Sapunova-Meier I, Ludolph AC, Brettschneider J. CSF proteome analysis in clinically isolated syndrome (CIS): candidate markers for conversion to definite multiple sclerosis. Neurosci Lett. 2009 Mar 13;452 (2):214-7
  • Urbanova M, Kalousova M, Zima T, Skibova J, Wohlfahrt P, Viklicky O. Fetuin-A early after renal transplantation. Kidney Blood Press Res. 2009;32 (3):217-22
  • Uz O, Kardesoglu E, Yiginer O, Bas S, Ipcioglu OM, Ozmen N, Aparci M, Cingozbay BY, Isilak Z, Cebeci BS. The relationship between coronary calcification and the metabolic markers of osteopontin, fetuin-A, and visfatin. Turk Kardiyol Dern Ars. 2009 Sep;37 (6):397-402
  • Wilund KR, Tomayko EJ, Wu PT, Ryong Chung H, Vallurupalli S, Lakshminarayanan B, Fernhall B. Intradialytic exercise training reduces oxidative stress and epicardial fat: a pilot study. Nephrol Dial Transplant. 2010 Aug;25 (8):2695-701
  • Wojtysiak-Duma B, Duma D, Burska A, Janicki K, Zakaszewska K, Skałecki P, Janicka L, Solski J. Fetuin-A in patients undergoing peritoneal dialysis with coronary artery calcification. Annales Universitatis Marie Cu. XXI, N 1, 68, 2008
  • Yang SJ, Hong HC, Choi HY, Yoo HJ, Cho GJ, Hwang TG, Baik SH, Choi DS, Kim SM, Choi KM. Effects of a three-month combined exercise programme on fibroblast growth factor 21 and fetuin-A levels and arterial stiffness in obese women. Clin Endocrinol (Oxf). 2011 Oct;75 (4):464-9
  • Yilmaz MI, Saglam M, Qureshi AR, Carrero JJ, Caglar K, Eyileten T, Sonmez A, Cakir E, Oguz Y, Vural A, Yenicesu M, Stenvinkel P, Lindholm B, Axelsson J. Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin. Nephrol Dial Transplant. 2008 May;23 (5):1621-7
  • Ziolkowska H, Brzewski M, Roszkowska-Blaim M. Determinants of the intima-media thickness in children and adolescents with chronic kidney disease. Pediatr Nephrol. 2008 May;23 (5):805-11
  • Ziolkowska H, Wojnar J, Panczyk-Tomaszewska M, Roszkowska-Blaim M. [Fetuin A in children with renal diseases]. Przegl Lek. 2006;63 Suppl 3:54-6

References to summary

  • Arnaud P, Kalabay L. Alpha2-HS glycoprotein: a protein in search of a function. Diabetes Metab Res Rev. 2002 Jul-Aug; 18(4): 311-4. Review.
  • Denecke B, Graber S, Schafer C, Heiss A, Woltje M, Jahnen-Dechent W. Tissue distribution and activity testing suggest a similar but not identical function of fetuin-B and fetuin-A. Biochem J. 2003 Nov 15; 376(Pt 1): 135-45.
  • Floege J, Ketteler M. Vascular calcification in patients with end-stage renal disease. Nephrol Dial Transplant. 2004 Aug;19 Suppl 5:V59-66
  • Geroldi D, Minoretti P, Bianchi M, Di Vito C, Reino M, Bertona M, Emanuele E. Genetic association of alpha2-Heremans-Schmid glycoprotein polymorphism with late-onset Alzheimer's disease in Italians. Neurosci Lett. 2005 Oct 7;386 (3):176-8
  • Heiss A, DuChesne A, Denecke B, Grotzinger J, Yamamoto K, Renne T, Jahnen-Dechent W. Structural basis of calcification inhibition by alpha 2-HS glycoprotein/fetuin-A. Formation of colloidal calciprotein particles. J Biol Chem. 2003 Apr 11;278 (15):13333-41
  • Ix JH, Shlipak MG, Brandenburg VM, Ali S, Ketteler M, Whooley MA. Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. Circulation. 2006 Apr 11;113 (14):1760-7
  • Jersmann HP, Dransfield I, Hart SP. Fetuin/alpha2-HS glycoprotein enhances phagocytosis of apoptotic cells and macropinocytosis by human macrophages. Clin Sci (Lond). 2003 Sep; 105(3): 273-8.
  • Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Bohm R, Metzger T, Wanner C, Jahnen-Dechent W, Floege J. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet. 2003 Mar 8; 361(9360): 827-33.
  • Kundranda MN, Henderson M, Carter KJ, Gorden L, Binhazim A, Ray S, Baptiste T, Shokrani M, Leite-Browning ML, Jahnen-Dechent W, Matrisian LM, Ochieng J. The serum glycoprotein fetuin-A promotes Lewis lung carcinoma tumorigenesis via adhesive-dependent and adhesive-independent mechanisms. Cancer Res. 2005 Jan 15;65 (2):499-506
  • Kwak JY, Ma TZ, Yoo MJ, Choi BH, Kim HG, Kim SR, Yim CY, Kwak YG. The comparative analysis of serum proteomes for the discovery of biomarkers for acute myeloid leukemia. Exp Hematol. 2004 Sep;32 (9):836-42
  • Lebreton JP, Joisel F, Raoult JP, Lannuzel B, Rogez JP, Humbert G. Serum concentration of human alpha 2 HS glycoprotein during the inflammatory process: evidence that alpha 2 HS glycoprotein is a negative acute-phase reactant. J Clin Invest. 1979 Oct;64 (4):1118-29
  • Mehrotra R, Westenfeld R, Christenson P, Budoff M, Ipp E, Takasu J, Gupta A, Norris K, Ketteler M, Adler S. Serum fetuin-A in nondialyzed patients with diabetic nephropathy: relationship with coronary artery calcification. Kidney Int. 2005 Mar;67 (3):1070-7
  • Osawa M, Tian W, Horiuchi H, Kaneko M, Umetsu K. Association of alpha2-HS glycoprotein (AHSG, fetuin-A) polymorphism with AHSG and phosphate serum levels. Hum Genet. 2005 Feb;116 (3):146-51
  • Osawa M, Umetsu K, Sato M, Ohki T, Yukawa N, Suzuki T, Takeichi S. Structure of the gene encoding human alpha 2-HS glycoprotein (AHSG). Gene. 1997 Sep 1;196 (1-2):121-5
  • Puchades M, Hansson SF, Nilsson CL, Andreasen N, Blennow K, Davidsson P. Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Brain Res Mol Brain Res. 2003 Oct 21;118 (1-2):140-6
  • Reynolds JL, Skepper JN, McNair R, Kasama T, Gupta K, Weissberg PL, Jahnen-Dechent W, Shanahan CM. Multifunctional roles for serum protein fetuin-a in inhibition of human vascular smooth muscle cell calcification. J Am Soc Nephrol. 2005 Oct;16 (10):2920-30
  • Schafer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J, Muller-Esterl W, Schinke T, Jahnen-Dechent W. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest. 2003 Aug; 112(3): 357-66.
  • Schinke T, Amendt C, Trindl A, Poschke O, Muller-Esterl W, Jahnen-Dechent W. The serum protein alpha2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. A possible role in mineralization and calcium homeostasis. J Biol Chem. 1996 Aug 23;271 (34):20789-96
  • Wang AY, Woo J, Lam CW, Wang M, Chan IH, Gao P, Lui SF, Li PK, Sanderson JE. Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients. Nephrol Dial Transplant. 2005 Aug;20 (8):1676-85
  • Zhou H, Pisitkun T, Aponte A, Yuen PS, Hoffert JD, Yasuda H, Hu X, Chawla L, Shen RF, Knepper MA, Star RA. Exosomal Fetuin-A identified by proteomics: a novel urinary biomarker for detecting acute kidney injury. Kidney Int. 2006 Nov;70 (10):1847-57

Registration form



Shopping cart

Your cart is empty.